OncoSec Medical (LTS:0KC7) ROCE % : -595.40% (As of Jan. 2023)

View and export this data going back to 2018. Start your Free Trial

What is OncoSec Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OncoSec Medical's annualized ROCE % for the quarter that ended in Jan. 2023 was -595.40%.

OncoSec Medical ROCE % Historical Data

The historical data trend for OncoSec Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical ROCE % Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

ROCE %

Get a 7-Day Free Trial

-216.02

-122.78

-191.05

-138.79

-117.98

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
ROCE %	Get a 7-Day Free Trial															-115.99	-145.12	-170.39	-282.78	-595.40

OncoSec Medical ROCE % Calculation

OncoSec Medical's annualized ROCE % for the fiscal year that ended in Jul. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2022 )		(A: Jul. 2021 )		(A: Jul. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2022 )		(A: Jul. 2021 )		(A: Jul. 2022 )
	=	-37.493	/	( ( (56.276 - 7.962)	+	(21.878 - 6.633) )	/ 2 )
	=	-37.493	/	( (48.314	+	15.245)	/ 2 )
	=	-37.493	/	31.7795
	=	-117.98 %

OncoSec Medical's ROCE % of for the quarter that ended in Jan. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2023 )		(Q: Oct. 2022 )		(Q: Jan. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2023 )		(Q: Oct. 2022 )		(Q: Jan. 2023 )
	=	-27.296	/	( ( (14.439 - 6.91)	+	(8.871 - 7.231) )	/ 2 )
	=	-27.296	/	( ( 7.529	+	1.64 )	/ 2 )
	=	-27.296	/	4.5845
	=	-595.40 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2023) EBIT data.

OncoSec Medical (LTS:0KC7) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OncoSec Medical ROCE % Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (LTS:0KC7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (LTS:0KC7) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ONCSQ:USA

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (LTS:0KC7) Headlines

No Headlines